Skip to main content

Internal Medicine Alert

RSS  

Articles

  • Measles Vaccination in Adults in 2025

    The Centers for Disease Control and Prevention has updated measles vaccination recommendations.

  • Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation

    An integrated nationwide medical and pharmacy claims database analysis of patients with new atrial fibrillation undergoing catheter ablation as first-line therapy has shown that 17% of patients required repeat ablation for recurrent atrial fibrillation despite the frequent use of antiarrhythmic drugs.

  • Ten-Year Outcomes of the SCOT-HEART Study

    The 10-year follow-up of the SCOT-HEART Study of new-onset chest pain patients randomized to standard care vs. the addition of coronary computed tomography angiography (CTA) has shown that coronary heart disease-related death, myocardial infarction, and other adverse cardiovascular outcomes are reduced with CTA use, perhaps because preventive therapy is increased.

  • Apomorphine Hydrochloride Injection (Onapgo)

    The U.S. Food and Drug Administration has approved apomorphine as a constant subcutaneous infusion for the treatment of advanced Parkinson’s disease with persistent motor fluctuations. It is the second subcutaneous infusion for this indication following foscarbidopa/foslevodopa (as Vyalev).

  • Determinants of Long-Term Outcome After Concussion

    This cohort study of U.S. veterans found that mild traumatic brain injuries occurring alongside psychological trauma are associated with long-term post-concussive symptoms and disability. The authors postulate that the traumatic context contributes to the development of post-traumatic stress disorder, which may in turn potentiate long-term sequelae.

  • Gabapentin vs. Duloxetine vs. Falls in Older Adults

    This retrospective study examining fall risk among older adults taking gabapentin compared to duloxetine finds gabapentin users exhibit a markedly lower risk of fall-related visits at six months (hazard ratio = 0.52) yet finds no difference in the incidence of severe falls.

  • Subtle but Real?

    The electrocardiogram (ECG) in the figure was obtained from an older man with intermittent chest pain that has awakened him from sleep. How would you interpret this ECG? Should you activate the cath lab?

  • Suzetrigine Tablets (Journavx)

    The U.S. Food and Drug Administration has approved suzetrigine, a first-in-class, non-opioid analgesic, to treat moderate to severe pain.

  • Treating Hereditary TTR Amyloid Polyneuropathy with Patisiran

    A five-year study on patisiran for hereditary transthyretin (TTR) amyloid polyneuropathy found that 65% of patients had stable or improved neuropathy, with better outcomes linked to early treatment. Despite efficacy, 19.4% of patients died. The study underscores the importance of early diagnosis and intervention in managing this progressive disease.

  • Cardiac and Paracardiac Structure in the SUMMIT Trial

    A cardiac magnetic resonance imaging study in a subgroup of the patients in the SUMMIT trial of tirzepatide in patients with heart failure with preserved ejection fraction has demonstrated that patients treated with tirzepatide had reduced left ventricular mass and paracardiac adipose tissue compared to placebo-treated patients, which may partially explain the reduction in heart failure events observed in the main SUMMIT trial.